Recent Developments in Mass-spectrometry-based Targeted Proteomics of Clinical Cancer Biomarkers

Overview

Journal Clin Proteomics

Publisher Biomed Central

Date 2024 Jan 29

PMID 38287260

Authors

Deborah Wenk

Charlotte Zuo

Thomas Kislinger

Lusia Sepiashvili

Affiliations

Soon will be listed here.

Abstract

Routine measurement of cancer biomarkers is performed for early detection, risk classification, and treatment monitoring, among other applications, and has substantially contributed to better clinical outcomes for patients. However, there remains an unmet need for clinically validated assays of cancer protein biomarkers. Protein tumor markers are of particular interest since proteins carry out the majority of biological processes and thus dynamically reflect changes in cancer pathophysiology. Mass spectrometry-based targeted proteomics is a powerful tool for absolute peptide and protein quantification in biological matrices with numerous advantages that make it attractive for clinical applications in oncology. The use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) based methodologies has allowed laboratories to overcome challenges associated with immunoassays that are more widely used for tumor marker measurements. Yet, clinical implementation of targeted proteomics methodologies has so far been limited to a few cancer markers. This is due to numerous challenges associated with paucity of robust validation studies of new biomarkers and the labor-intensive and operationally complex nature of LC-MS/MS workflows. The purpose of this review is to provide an overview of targeted proteomics applications in cancer, workflows used in targeted proteomics, and requirements for clinical validation and implementation of targeted proteomics assays. We will also discuss advantages and challenges of targeted MS-based proteomics assays for clinical cancer biomarker analysis and highlight some recent developments that will positively contribute to the implementation of this technique into clinical laboratories.

Citing Articles

Mass Spectrometry-Based Proteomics in Clinical Diagnosis of Amyloidosis and Multiple Myeloma: A Review (2012-2024).

Kratka K, Sistik P, Olivkova I, Kusnierova P, Svagera Z, Stejskal D J Mass Spectrom. 2025; 60(3):e5116.

PMID: 39967472 PMC: 11836596. DOI: 10.1002/jms.5116.

Comprehensive Metabolomic Profiling in Adults with X-Linked Hypophosphatemia: A Case-Control Study.

Lopez-Romero L, Broseta J, Roca-Marugan M, Manez Ramirez N, Hernandez-Jaras J Biomedicines. 2025; 13(1).

PMID: 39857606 PMC: 11759187. DOI: 10.3390/biomedicines13010022.

The Enzyme Effect: Broadening the Horizon of MS Optimization to Nontryptic Digestion in Proteomics.

Nagy K, Sandor P, Vekey K, Drahos L, Revesz A J Am Soc Mass Spectrom. 2025; 36(2):299-308.

PMID: 39803703 PMC: 11808764. DOI: 10.1021/jasms.4c00396.

Proteomic Signatures of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Narrative Review.

Dourdouna M, Tatsi E, Syriopoulou V, Michos A Children (Basel). 2024; 11(10).

PMID: 39457139 PMC: 11505985. DOI: 10.3390/children11101174.

Diagnosis of invasive encapsulated follicular variant papillary thyroid carcinoma by protein-based machine learning.

Nguyen T, Le M, Roytrakul S, Shuangshoti S, Kitkumthorn N, Keelawat S J Pathol Transl Med. 2024; 59(1):39-49.

PMID: 39440350 PMC: 11736282. DOI: 10.4132/jptm.2024.09.14.

References

Brzhozovskiy A, Kononikhin A, Bugrova A, Kovalev G, Pierre-Olivier Schmit , Kruppa G . The Parallel Reaction Monitoring-Parallel Accumulation-Serial Fragmentation (prm-PASEF) Approach for Multiplexed Absolute Quantitation of Proteins in Human Plasma. Anal Chem. 2022; 94(4):2016-2022. DOI: 10.1021/acs.analchem.1c03782. View

Sun L, Zhu G, Yan X, Mou S, Dovichi N . Uncovering immobilized trypsin digestion features from large-scale proteome data generated by high-resolution mass spectrometry. J Chromatogr A. 2014; 1337:40-7. PMC: 4000775. DOI: 10.1016/j.chroma.2014.02.014. View

Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y . Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics. PLoS One. 2016; 11(8):e0161009. PMC: 5007017. DOI: 10.1371/journal.pone.0161009. View

Abbatiello S, Schilling B, Mani D, Zimmerman L, Hall S, MacLean B . Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma. Mol Cell Proteomics. 2015; 14(9):2357-74. PMC: 4563721. DOI: 10.1074/mcp.M114.047050. View

Swearingen K, Moritz R . High-field asymmetric waveform ion mobility spectrometry for mass spectrometry-based proteomics. Expert Rev Proteomics. 2012; 9(5):505-17. PMC: 4777519. DOI: 10.1586/epr.12.50. View

Manza L, Stamer S, Ham A, Codreanu S, Liebler D . Sample preparation and digestion for proteomic analyses using spin filters. Proteomics. 2005; 5(7):1742-5. DOI: 10.1002/pmic.200401063. View

Ducret A, James I, Wilson S, Feilke M, Tebbe A, Dybowski N . Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial. PLoS One. 2019; 14(3):e0213892. PMC: 6428264. DOI: 10.1371/journal.pone.0213892. View

Furey A, Moriarty M, Bane V, Kinsella B, Lehane M . Ion suppression; a critical review on causes, evaluation, prevention and applications. Talanta. 2013; 115:104-22. DOI: 10.1016/j.talanta.2013.03.048. View

Chiu H, Tsai Y, Lo C, Lin C, Tsai I, Kuo C . Development of an efficient mAb quantification assay by LC-MS/MS using rapid on-bead digestion. Anal Chim Acta. 2022; 1193:339319. DOI: 10.1016/j.aca.2021.339319. View

10.

Liebler D, Zimmerman L . Targeted quantitation of proteins by mass spectrometry. Biochemistry. 2013; 52(22):3797-806. PMC: 3674507. DOI: 10.1021/bi400110b. View

11.

Lone S, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S . Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022; 21(1):79. PMC: 8932066. DOI: 10.1186/s12943-022-01543-7. View

12.

Martinez-Garcia E, Lesur A, Devis L, Cabrera S, Matias-Guiu X, Hirschfeld M . Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment. Clin Cancer Res. 2017; 23(21):6458-6467. DOI: 10.1158/1078-0432.CCR-17-0474. View

13.

Di Meo A, Diamandis E, Rodriguez H, Hoofnagle A, Ioannidis J, Lopez M . What is wrong with clinical proteomics?. Clin Chem. 2014; 60(10):1258-66. DOI: 10.1373/clinchem.2014.225185. View

14.

Sinha A, Hussain A, Ignatchenko V, Ignatchenko A, Tang K, Ho V . N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer. Cell Syst. 2019; 8(4):345-351.e4. DOI: 10.1016/j.cels.2019.03.011. View

15.

Shuford C, Johnson J, Thompson J, Holland P, Hoofnagle A, Grant R . More sensitivity is always better: Measuring sub-clinical levels of serum thyroglobulin on a µLC-MS/MS system. Clin Mass Spectrom. 2021; 15:29-35. PMC: 8601006. DOI: 10.1016/j.clinms.2020.01.001. View

16.

van Poppel H, Roobol M, Chapple C, Catto J, Ndow J, Sonksen J . Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021; 80(6):703-711. DOI: 10.1016/j.eururo.2021.07.024. View

17.

Macklin A, Khan S, Kislinger T . Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clin Proteomics. 2020; 17:17. PMC: 7247207. DOI: 10.1186/s12014-020-09283-w. View

18.

Stephan C, Kohl M, Turewicz M, Podwojski K, Meyer H, Eisenacher M . Using Laboratory Information Management Systems as central part of a proteomics data workflow. Proteomics. 2010; 10(6):1230-49. DOI: 10.1002/pmic.200900420. View

19.

van den Broek I, Fu Q, Kushon S, Kowalski M, Millis K, Percy A . Application of volumetric absorptive microsampling for robust, high-throughput mass spectrometric quantification of circulating protein biomarkers. Clin Mass Spectrom. 2024; 4-5:25-33. PMC: 11322776. DOI: 10.1016/j.clinms.2017.08.004. View

20.

Becker G . Stable isotopic labeling of proteins for quantitative proteomic applications. Brief Funct Genomic Proteomic. 2008; 7(5):371-82. DOI: 10.1093/bfgp/eln047. View